Therapy Areas: Inflammatory Diseases
Bambusa Therapeutics names new CFO
20 March 2026 - Bambusa Therapeutics Inc, a clinical-stage biotechnology company developing next-generation bispecific antibodies for immunology and inflammation (I&I), announced on Thursday the a...
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
19 March 2026 - Swedish life science tools company Mabtech announced on Wednesday a strategic collaboration with Sai Life Sciences, a global Contract Research Organisation (CRO).Under the agreement, S...
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
16 March 2026 - Vimgreen Pharmaceuticals, a Chinese developer of novel therapeutics targeting adenosine signalling pathways, with a focus on addressing unmet medical needs in neurodegenerative, metabo...
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
13 March 2026 - Clinical-stage biotechnology company Inimmune Corporation announced on Thursday the completion of enrolment and dosing of the first patient in its Phase 2 allergen challenge chamber tr...
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
12 March 2026 - Swedish clinical-stage pharmaceutical company Gesynta Pharma AB announced on Wednesday that the first patient has been dosed in its its Phase 2 clinical proof-of-concept trial of vipog...
Immunic granted European patent for vidofludimus calcium dosing regimens
...